Proteomics Identifies LUC7L3 as a Prognostic Biomarker for Hepatocellular Carcinoma

Alternative splicing has been shown to participate in tumor progression, including hepatocellular carcinoma. The poor prognosis of patients with HCC calls for molecular classification and biomarker identification to facilitate precision medicine. We performed ssGSEA analysis to quantify the pathway...

Full description

Saved in:
Bibliographic Details
Published inCurrent Issues in Molecular Biology Vol. 46; no. 5; pp. 4004 - 4020
Main Authors Hou, Yushan, Wang, Siqi, Zhang, Yiming, Huang, Xiaofen, Zhang, Xiuyuan, He, Fuchu, Tian, Chunyan, Sun, Aihua
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 01.05.2024
Subjects
alternative splicing
Development and progression
Diseases
hepatocellular carcinoma
Hepatoma
International economic relations
LUC7L3
prognostic biomarker
Relapse
RNA
RRM2
Scientific equipment and supplies industry
United States
China
LUC7L3
prognostic biomarker
RRM2
alternative splicing
hepatocellular carcinoma
Online AccessGet full text

Cover

More Information
Summary:Alternative splicing has been shown to participate in tumor progression, including hepatocellular carcinoma. The poor prognosis of patients with HCC calls for molecular classification and biomarker identification to facilitate precision medicine. We performed ssGSEA analysis to quantify the pathway activity of RNA splicing in three HCC cohorts. Kaplan-Meier and Cox methods were used for survival analysis. GO and GSEA were performed to analyze pathway enrichment. We confirmed that RNA splicing is significantly correlated with prognosis, and identified an alternative splicing-associated protein LUC7L3 as a potential HCC prognostic biomarker. Further bioinformatics analysis revealed that high LUC7L3 expression indicated a more progressive HCC subtype and worse clinical features. Cell proliferation-related pathways were enriched in HCC patients with high LUC7L3 expression. Consistently, we proved that LUC7L3 knockdown could significantly inhibit cell proliferation and suppress the activation of associated signaling pathways in vitro. In this research, the relevance between RNA splicing and HCC patient prognosis was outlined. Our newly identified biomarker LUC7L3 could provide stratification for patient survival and recurrence risk, facilitating early medical intervention before recurrence or disease progression.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1467-3045
1467-3037
1467-3045
DOI:10.3390/cimb46050247